Original release date: November 12, 2020
Access to this course expires on: May 12, 2021 at 11:59 PM Pacific Time
Breast carcinoma is one of the leading causes of cancer-related death in women worldwide. After the histologic assessment and diagnosis of an invasive breast carcinoma, biomarkers are performed and play an essential role in treatment decisions. ER, PR and HER2 are the main biomarkers tested in all invasive breast cancers and AR is an emerging biomarker without published testing guidelines yet. ASCO and CAP have convened expert panels and developed recommendations to ensure optimal testing and accurate interpretation of ER, PR and HER2 in breast cancer. Review of the current biomarker testing guidelines and clinical implications will be discussed.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Dara S. Ross, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.